INTRODUCTION {#s1}
============

Diffuse large B-cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is derived from germinal centre or post-germinal centre B cells \[[@R1]\]. DLBCLs are clinically and molecular heterogenous \[[@R1]--[@R4]\]. Long-term disease-free survival is now a reality for at least 50 percent of patients. However, approximately 30 percent of patients with DLBCL, mainly those with advanced disease and those who relapse, will not respond appropriately to current treatments \[[@R4], [@R5]\]. A better understanding of the specific pathways underlying the malignant phenotype in DLBCL is urgently required. This would allow not only the development of novel targeted therapeutic approaches for defined subgroups of DLBCL, but also the identification of new biomarkers \[[@R6]\].

Activation of B lymphocytes is associated with rapid proliferation, somatic hypermutation and targeted DNA double strand breaks in the immunoglobulin (Ig) locus. This process is under tight spatial and temporal control achieved by extracellular signals sensed via B cell receptor (BCR), CD40, Toll-like receptors (TLR), B-cell activating factor (BAFF) receptor, interleukin-21 (IL21) receptor and cell intrinsic mechanisms \[[@R1], [@R7]--[@R13]\]. Molecular signatures suggest that specific signaling networks and survival mechanisms exist in DLBCL, caused either by extracellular signals from the lymphoma microenvironment or related pathway mutations within the lymphoma cells, or both \[[@R1], [@R13]\].

Based on the cell of origin two main molecularly defined subgroups of DLBCLs can be described: activated B cell (ABC) - like and germinal centre B cell (GCB) -- like DLBCL \[[@R14]\]. This cell-of-origin-approach is driven by class labels. In parallel, signatures such as stroma, host response, OxPhos and BCR/proliferation or Jak/STAT and IKK have been described by comprehensive consensus clustering, and identify the lymphoma microenvironment as a defining feature \[[@R15]--[@R19]\]. The level of c-Myc activity also allows the subdivision of DLBCL \[[@R20]--[@R23]\]; a high c-Myc index or a high number of Myc positive lymphoma cells is associated with shorter survival \[[@R20]--[@R23]\], but the subentities defined by Myc expression only partly overlap with the ABC/GCB-like signatures. Although these studies predict activity of different oncogenic pathways for DLBCL subtypes the functional consequences of differential gene expression are still poorly understood \[[@R15], [@R18], [@R19], [@R24]--[@R27]\],

Recently we introduced guided clustering as a strategy that integrates experimental, clinical and global gene expression data to investigate aggressive non-Hodgkin lymphoma (NHL) \[[@R28]--[@R30]\]. This approach does not utilize the class labels from the clinical data (e.g. disease types or clinical outcomes) to derive a molecular signature, but instead is based on the underlying biology for example the activity of an entire pathway or pathway networks established by cell perturbation experiments. For example, in our recent proof of principle analysis we were able to captured quantitatively a link between BCL-6 gene regulation and TLR signaling. The combined analysis of experimental and global gene expression data can allow the development of functional hypotheses \[[@R29], [@R31]\]. Therefore, transcriptional modules (groups of coherent expressed genes) can be described as potential major oncogenic hubs that are conserved between patients.

The present study aimed to extract functional information on oncogenic pathway activities in distinct DLBCL cases based on gene expression from primary tumours and multiple *in vitro* interventions. To do this the guided clustering-driven identification of transcriptional modules was extended and multiple single *in vitro* interventions were combined *in silico* to identify transcriptional modules conserved between patients but dominantly affected by for example BCR signaling but not TLR, IL21, CD40L or BAFF. This is to enable the assessment of pathway specific activities in primary lymphoma cases.

A new regulatory circuit in B cells was identified. A group of dominantly suppressed genes upon BCR activation is involved in an overall diminished capacity of the cells to enter mitosis, leading to defects in metaphase as well as increased chromosomal aberrations. In a subgroup of GCB-like DLBCL with low Myc activity this new regulatory circuit is dominant. This regulatory circuit is nearly absent in BL but active in c-Myc^high^ DLBCLs. Our data supports the view that BCR signaling is context dependent and capable not only of promoting cell survival and proliferation but also delaying cell cycle progression thereby potentially increasing chromosomal aberrations. It further underpins the notion that defined pathways stimulated by microenvironmental factors activating the BCR are involved in DLBCL development and that these pathways might be of therapeutic relevance. Our analysis shows how guided clustering lead to the discovery of biomarkers for cancer stratification.

RESULTS {#s2}
=======

A combined analysis of experimental and tumour derived global gene expression data identifies a set of genes specifically suppressed by BCR activation {#s2_1}
------------------------------------------------------------------------------------------------------------------------------------------------------

Ligands activating pattern recognition receptors, BCR, CD40, BAFF-receptors and IL21 receptor are well known mediators of signalling in B cells and important components of the GC B cell reaction. Furthermore, it is well known that elements of the corresponding signalling pathways are mutated in DLBCL \[[@R1], [@R7]--[@R13]\]. Thus, the signalling pathways activated by these factors represent promising candidates for the identification of oncogenic pathway signatures in DLBCL via guided clustering. To answer these questions, as a model cell line, BL2 was chosen. The criteria for their selection were: absence or low pathway activity, a strong signal induction by stimuli, and measurable global gene expression changes suitable for bioinformatic analysis as we have previously described \[[@R32]\].

Microarray data sets obtained from human transformed germinal centre B cells (BL2) stimulated with CD40L, BAFF, IL21, αIgM F(ab)~2~ fragments and lipopolysaccharide (LPS) were processed as described previously, combined, and analysed by guided clustering using large-scale gene expression data from 175 DLBCL patients \[[@R28], [@R32]\]. The patients were selected from the MMML-cohort and are representative of non-mBLs without chromosomal *MYC* translocations \[[@R30]\]. Guided clustering was performed in the following way: the guiding datasets were obtained from *in vitro* stimulated BL2 cells and only genes driven dominantly by one stimuli, but not the others, included. These data sets were integrated with gene expression profiles of primary lymphoma material. Ten different gene clusters were identified characterized by increased or suppressed gene expression in experiments and concordantly expressed in lymphoma patients: CD40.1, CD40.2, IL21.1, IL21.2, BAFF.1, BAFF.2, BCR.1, BCR.2, LPS.1 and LPS.2 (Figure [1A](#F1){ref-type="fig"}, Table [I](#T1){ref-type="table"}). The suffix ".1" denotes genes mainly suppressed and ".2" those genes mainly activated (Table [I](#T1){ref-type="table"}, [Supplementary Table S1](#SD2){ref-type="supplementary-material"}). These clusters most likely represent surrogates of pathway activity dominated by one of the stimuli. To delineate so far undescribed biological outcomes the following experiments were focused on αIgM driven suppression of gene expression.

![Guided Clustering identifies gene clusters dominantly affected by one specific intervention\
**A.** Heatmap representation of the gene expression levels for the genes within the ten transcriptional modules identified by guided clustering analysis. Global gene expression of stimulated BL2 cells and gene expression profiles from 175 lymphoma patients without Myc-translocations \[[@R28], [@R30]\]. BL2 cells treated with αIgM treatment, CD40L, LPS, BAFF and IL21. Each column in the heatmap represents a gene and each row represents a microarray sample. Yellow and blue indicate high and low gene expression. Heatmap shows the gene expression of the corresponding cluster genes in stimulated BL2 cells compared to unstimulated cells. **B.** A heatmap representation of BCR.1 genes in gene expression profiles of 137 primary lymphoma. The patient samples are ordered according to their increasing BCR.1 index starting with the lowest index on the very left end of the heatmap \[[@R30]\]. **C.** Gene ontology based analysis of the fraction of genes from the BCR.1 gene cluster associated with the cell cycle. GO Term analysis gives frequency of BCR.1 genes involved in different cell cycle phases (information taken from [www.cyclebase.org](http://www.cyclebase.org))(for additional details see also [Supplementary Table S2](#SD3){ref-type="supplementary-material"}).](oncotarget-07-47061-g001){#F1}

###### Identification of different clusters of genes displaying a coherent expression across patient profiles affected by multiple *in vitro* interventions using guided clustering

  intervention   Index name   Number of genes coherently expressed in DLBCL   Gene expression changes in BL2 cells
  -------------- ------------ ----------------------------------------------- --------------------------------------
  αIgM                                                                        
                 BCR.1        288                                             suppressed
                 BCR.2        286                                             activated
  CD40L                                                                       
                 CD40.1       288                                             suppressed
                 CD40.2       71                                              activated
  BAFF                                                                        
                 BAFF.1       255                                             suppressed
                 BAFF.2       122                                             activated
  IL21                                                                        
                 IL21.1       148                                             suppressed
                 IL21.2       13                                              activated
  LPS                                                                         
                 LPS.1        34                                              suppressed
                 LPS.2        37                                              activated

Next the 137 DLBCL patient samples used for guided clustering were sorted according to an individual index value derived from BCR.1. This index reflects the extent to which BCR.1 genes are expressed within an individual sample. A high BCR.1 index indicates strong down-regulation of the BCR.1 genes. Finally, lymphoma samples were sorted according to their individual index (Figure [1B](#F1){ref-type="fig"}). This results in a spectrum of lymphoma samples ranging from low to high BCR.1 index scores. A substantial number of analysed patient samples is characterized by a corresponding strong BCR.1 signal.

Molecular functions, biological processes, cellular components and pathways of BCR.1 genes were identified by gene ontology (GO) based gene set enrichment analyses (Table [II](#T2){ref-type="table"}, [Supplementary Table S2](#SD3){ref-type="supplementary-material"}). Among the top 100 BCR.1 genes, the most significantly enriched gene sets corresponded to biological processes which included cell cycle checkpoints, microtubule-based processes, microtubule cytoskeleton organization, spindle organization, mitotic chromosome segregation or sister chromatid segregation as well as response to DNA damage stimuli, organelle organization or metabolic processes (Table [II](#T2){ref-type="table"}). In Figure [1C](#F1){ref-type="fig"} BCR.1 index genes associated with cell cycle regulatory functions are presented. Genes are grouped according to the corresponding cell cycle phases in which they are involved, demonstrating that more than 40% of cell cycle regulatory genes within this gene cluster belong to G2 and M cell cycle regulation.

###### Genes of coherent expression across patient profiles reflecting the activity of a branch of B cell receptor signaling

  ---- --------- ---- ---------- ----- ---------- ----- ----------- ----- ---------- ----- ------------
  1    XPO1      50   RFC3       99    CLINT1     148   SFRS4       197   BBS10      246   MRPL49
  2    PMS1      51   ECT2       100   DLAT       149   HSPH1       198   ZNF638     247   CSE1L
  3    RNASEN    52   DSCC1      101   RIOK2      150   FOSL1       199   SRBD1      248   PLA2G12A
  4    LBR       53   C12orf48   102   CKAP2      151   KIAA0406    200   GTF2E1     249   ELP4
  5    CETN3     54   WRAP53     103   NARS2      152   DSN1        201   MEN1       250   UBTF
  6    DCK       55   PARP2      104   CEP76      153   PRPF4B      202   LSM2       251   GTF3C1
  7    GPN3      56   TRIP13     105   CACYBP     154   C13orf34    203   SRPK1      252   BCOR
  8    SLBP      57   KIF11      106   TMEM97     155   BAG2        204   TTRAP      253   C5orf22
  9    RHOT1     58   AASDHPPT   107   POLE2      156   ZNHIT3      205   ZNF184     254   TTC33
  10   CAND1     59   FARSA      108   USP13      157   PDHB        206   MICB       255   PSME4
  11   RACGAP1   60   CTCF       109   RAD1       158   CCDC56      207   TUBD1      256   PPM1B
  12   KIF20A    61   RNASEH2A   110   GCDH       159   CUTC        208   NFYB       257   PIAS4
  13   AURKA     62   NEIL3      111   CPOX       160   C14orf104   209   KIF18B     258   WBP4
  14   HMMR      63   STIL       112   CLPX       161   COX11       210   PRDM10     259   ACAP2
  15   NDC80     64   TARDBP     113   MORC2      162   CDK8        211   HMGN4      260   GRSF1
  16   CDC20     65   ARMC1      114   RFC5       163   C8orf41     212   RAD54B     261   GADD45GIP1
  17   CENPA     66   MRPL35     115   RAD51C     164   AURKAIP1    213   DTWD1      262   MSH2
  18   PLK1      67   WDR67      116   RCN2       165   IMP3        214   BRD8       263   DTYMK
  19   NEK2      68   NUP37      117   PIGF       166   MINA        215   TRMT61B    264   FRAT2
  20   CCNA2     69   MRPL12     118   ACTR6      167   PUM2        216   RNF34      265   STAMBP
  21   KIF18A    70   RAD54L     119   CDC73      168   DHX29       217   CDC27      266   C17orf75
  22   RMI1      71   C16orf53   120   MDM1       169   COASY       218   EXOC1      267   FANCL
  23   PBK       72   ALG6       121   KIAA0528   170   THAP7       219   SACM1L     268   SFRS2B
  24   PRC1      73   TROAP      122   PARG       171   MRPS34      220   VPS33B     269   HMBS
  25   BUB1B     74   CDC7       123   THAP11     172   CCDC51      221   SUCLA2     270   PAAF1
  26   PLK4      75   RFC4       124   C12orf52   173   MRPL17      222   MRS2       271   NAA40
  27   CDCA8     76   UNG        125   PTCD3      174   COIL        223   C6orf211   272   NDUFS3
  28   NCAPH     77   PPAT       126   CASP6      175   ATMIN       224   HMGB3      273   DUT
  29   TMEM48    78   FASTKD1    127   CTR9       176   SMARCAL1    225   GEMIN6     274   STRA13
  30   OIP5      79   KIF15      128   MRPL46     177   COQ9        226   MRPS16     275   HADH
  31   CEP55     80   ANP32A     129   GPSM2      178   COBRA1      227   MCM10      276   SEPHS1
  32   KIF14     81   SRRD       130   NDUFC1     179   MED20       228   AP1AR      277   ABHD10
  33   ESPL1     82   LRRC47     131   UBE2G1     180   CCDC99      229   C4orf27    278   SLC4A1AP
  34   POLA2     83   PREB       132   PRPSAP1    181   SIP1        230   FASTKD3    279   STRADA
  35   FEN1      84   ZC3H14     133   NCAPD3     182   FANCG       231   CLCN3      280   CBX1
  36   BRCA1     85   TTK        134   DPF2       183   MCM2        232   PRMT5      281   MRPS27
  37   TUBG1     86   EFTUD1     135   HEATR3     184   CRIPT       233   TDP1       282   WRB
  38   MRPL16    87   OSBPL11    136   SHCBP1     185   GAPVD1      234   LARS2      283   DERA
  39   TACC3     88   MYCBP      137   C4orf41    186   CNP         235   BARD1      284   SAR1B
  40   SAC3D1    89   DYNLL1     138   SKP2       187   RAB11A      236   MSH3       285   MAP3K4
  41   ASPM      90   NIF3L1     139   MTX2       188   MRPS31      237   MPHOSPH6   286   KIAA1279
  42   WDHD1     91   MRFAP1L1   140   MUDENG     189   MRPL34      238   MTIF2      287   PPCS
  43   BIRC5     92   NARG2      141   C15orf44   190   PHB         239   ATR        288   C5orf15
  44   CCNB1     93   SPAST      142   GINS1      191   POP4        240   PPP2R5E          
  45   ASF1B     94   ZW10       143   ZWILCH     192   AGGF1       241   PSMC6            
  46   ORC1L     95   ELF2       144   MRPL18     193   KIF22       242   ZNF107           
  47   KIF2C     96   ADH5       145   PEX14      194   POP7        243   EIF2B4           
  48   CDCA3     97   ORC4L      146   TOMM70A    195   DDX23       244   C9orf40          
  49   FOXM1     98   ORC2L      147   TSN              ZBED5       245   RTF1             
  ---- --------- ---- ---------- ----- ---------- ----- ----------- ----- ---------- ----- ------------

Shown are the genes of the newly identified transcriptional module called BCR.1. For all transcriptional modules please refer to TABLE E1.

Verification and validation of gene expression after αIgM treatment reveals the downregulation of BCR.1 index genes {#s2_2}
-------------------------------------------------------------------------------------------------------------------

Table [III](#T3){ref-type="table"} summarises the fold changes in expression of genes from the BCR.1 cluster involved in cell cycle regulation that were suppressed by αIgM treatment of BL2 cells.

###### Genes involved in different aspects of cell cycle regulation as described by guided clustering for BCR.1

       Gene symbol           Name                                                                Function in cell cycle and related processes                                                                                                                                                                                                                                Fold change (log~2~FC)   Fold change (log~2~FC)
  ---- --------------------- ------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ ------------------------
  1    ASPM                  asp (abnormal spindle) homolog                                      role in mitotic spindle regulation and coordination of mitotic processes                                                                                                                                                                                                    −0,51                    −0,45
  2    ATMIN                 ATM interactor                                                      ATM/ATR-substrate CHEK2-interacting zinc finger protein; Plays a crucial role in cell survival and RAD51 foci formation in response to methylating DNA damage. Involved in regulating the activity of ATM in the absence of DNA damage                                      −0,39                    n.a.
  3    AURKA                 Aurora-kinase A                                                     Mitotic serine/threonine kinases that contributes to the regulation of mitosis                                                                                                                                                                                              −0,68                    −1,03
  4    BARD1                 BRCA1 associated RING domain 1                                      Constitutes together with BRCA1 an Ubiquitin E3 ligase                                                                                                                                                                                                                      −0,68                    −0,53
  5    BCOR                  BCL6 corepressor                                                    Transcriptional corepressor                                                                                                                                                                                                                                                 −0,69                    −0,43
  6    BIRC5/Survivin        baculoviral IAP repeat containing 5                                 Component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis                                                                                                                                                                     −0,45                    −0,44
  7    BRCA1                 breast and ovarian cancer susceptibility protein 1                  Constitutes together with BARD1 an ubiquitin E3 ligase. Involved in DNA repair and in the regulation of mitosis.                                                                                                                                                            −0,44                    −0,32
  8    BUB1B/MAD3L/BUBR1     budding uninhibited by benzimidazoles 1 homolog beta                Essential component of the mitotic spindle assembly checkpoint                                                                                                                                                                                                              −0,37                    −0,608
  9    C12orf52              RBP-J interacting and tubulin associated                            Tubulin-binding protein that acts as a negative regulator of Notch signaling pathway                                                                                                                                                                                        −0,83                    n.a.
  10   C13orf34/bora         aurora kinase A activator                                           Required for the activation of AURKA at the onset of mitosis                                                                                                                                                                                                                −0,42                    −0,417
  11   CCNA2                 Cyclin A2                                                           binds and activates CDK1 or CDK2 kinases, and thus promotes both cell cycle G1/S and G2/M transitions                                                                                                                                                                       −0,42                    −0,57
  12   CCNB1                 Cyclin B1                                                           Binds and activates CDK1, Eessential for the control of the cell cycle at the G2/M (mitosis) transition                                                                                                                                                                     −0,67                    −0,67
  13   CDC20                 cell division cycle 20 homolog                                      In metaphase the MAD2L1-CDC20-APC/C ternary complex is inactive and in anaphase the CDC20-APC/C binary complex is active in degrading substrates                                                                                                                            −0,57                    −0,87
  14   CDC27                 Anaphase-promoting complex subunit 3                                Subunit of the APC/C, cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase                                                                                                                                                   −0,27                    −0,52
  15   CDC7                  cell division cycle 7 homolog                                       G1/S phase transition                                                                                                                                                                                                                                                       −0,35                    −0,70
  16   CDCA3                 Trigger of mitotic entry protein 1                                  F-box-like protein which is required for entry into mitosis. Acts by participating in E3 ligase complexes                                                                                                                                                                   −0,54                    −0,66
  17   CENPA                 centromere protein A                                                Histone-like protein, Required for recruitment and assembly of kinetochore proteins, mitotic progression and chromosome segregation                                                                                                                                         −0,52                    −1,05
  18   CETN3                 centrin                                                             located at the centrosome of interphase and mitotic cells, where it plays a fundamental role in centrosome duplication                                                                                                                                                      −0,99                    −0,67
  19   COBRA1                cofactor of BRCA1                                                   Essential component of the NELF complex, a complex that negatively regulates the elongation of transcriptionby RNA polymerase II                                                                                                                                            −0,37                    n.a.
       COIL                  coilin                                                              During mitosis, CBS disassemble, coinciding with a mitotic-specific phosphorylation of p80coilin                                                                                                                                                                            n.a                      −0,23
  20   CSE1L                 CSE1 chromosome segregation 1-like                                  may play a role both in apoptosis and in cell proliferation                                                                                                                                                                                                                 −0,34                    −0,37
  21   DSCC1                 Defective in sister chromatid cohesion protein 1                    couple DNA replication to sister chromatid cohesion through regulation of the acetylation of the cohesin subunit SMC3                                                                                                                                                       −0,55                    −0,37
  22   DSN1                  MIND kinetochore complex component, homolog (S. cerevisiae)         MIND kinetochore complex component                                                                                                                                                                                                                                          −0,69                    −0,41
  23   ECT2/ARH-GEF31        Epithelial cell-transforming sequence 2 oncogene                    Required for signal transduction pathways involved in the regulation of cytokinesis                                                                                                                                                                                         −0,31                    −0,70
  24   ESPL1                 extra spindle pole bodies homolog 1                                 Caspase-like protease, which plays a central role in the chromosome segregation by cleaving the SCC1/RAD21 subunit of the cohesin complex at the onset of anaphase                                                                                                          −0,35                    −0,42
  25   FANCG                 Fanconi anemia, complementation group L                             maintenance of normal chromosome stability                                                                                                                                                                                                                                  −0,51                    −0,42
  26   FANCL                 Fanconi anemia, complementation group L                             mediates monoubiquitination of FANCD2, a key step in the DNA damage pathway                                                                                                                                                                                                 −0,72                    −0,65
  27   FOSL1/FRA1            FOS-like antigen 1                                                  regulators of cell proliferation                                                                                                                                                                                                                                            −0,28                    +0,22
  28   FOXM1                 forkhead box M1                                                     Transcriptional factor regulating the expression of cell cycle genes essential for DNA replication and mitosis                                                                                                                                                              n.a                      −0,33
  29   FRAT2                 frequently rearranged in advanced T-cell lymphomas 2                Positively regulates the Wnt signaling pathway by stabilizing beta-catenin through the association with GSK-3                                                                                                                                                               −0,96                    n.a.
  30   GADD45GIP1                                                                                growth arrest and DNA-damage-inducible, gamma interacting protein 1                                                                                                                                                                                                         −1,56                    n.a.
  31   HMMR/RHAMM            hyaluronan-mediated motility receptor                               Receptor protein and associated with mitotic spindles                                                                                                                                                                                                                       −0,86                    −0,99
  32   KIAA0406              TELO2 interacting protein 1                                         Regulator of the DNA damage response                                                                                                                                                                                                                                        −0,32                    n.a.
  33   KIF11/KSP/Eg5         kinesin family member 11                                            Motor protein required for establishing a bipolar spindle.                                                                                                                                                                                                                  n.a                      −0,71
  34   KIF14                 kinesin family member 14                                            Plays an essential role in cytokinesis                                                                                                                                                                                                                                      −0,45                    −0,75
       KIF15                 HKLP2, kinesin family member 15                                     Plus-end directed kinesin-like motor enzyme involved in mitotic spindle assembly                                                                                                                                                                                            −0,67                    −0,51
  35   KIF18A                kinesin family member 18A                                           Microtubule-depolymerizing kinesin which plays a role in chromosome congression.                                                                                                                                                                                            −0,56                    −0,38
  36   KIF18B                Kinesin family member 18B                                           Microtubule-depolymerizing kinesin                                                                                                                                                                                                                                          n.a                      −0,49
  37   KIF20A                Rab6-interacting kinesin-like protein                               Mitotic kinesin required for chromosome passenger complex (CPC)-mediated cytokinesis                                                                                                                                                                                        −1,65                    −1,26
  38   KIF22                 Kinesin family member 22                                            movements of chromosomes during mitosis                                                                                                                                                                                                                                     −0,36                    −0,27
  39   KIF2C/MCAK            Mitotic centromere-associated kinesin                               Microtubule depolymerase, Regulates the turnover of microtubules at kinetochores                                                                                                                                                                                            n.a                      −0,36
  40   MINA                  MYC induced nuclear antigen                                         Involved in cellular proliferation                                                                                                                                                                                                                                          −0,64                    n.a.
  41   MYCBP                 MYC-binding protein                                                 May control the transcriptional activity of MYC                                                                                                                                                                                                                             −0,33                    −0,97
  42   NEK2                  NIMA (never in mitosis gene a)-related kinase 2                     control of centrosome separation and bipolar spindle formation in mitotic cells                                                                                                                                                                                             −0,64                    −0,58
  43   NCAPD3                non-SMC condensin II complex, subunit D3                            Regulatory subunit of the condensin-2 complex, a complex which establishes mitotic chromosome architecture and is involved in physical rigidity of the chromatid axis                                                                                                       n.a                      −0,24
  44   NCAPH                 non-SMC condensin I complex, subunit H                              Regulatory subunit of the condensin complex, a complex required for conversion of interphase chromatin into mitotic-like condense chromosomes                                                                                                                               n.a                      −0,43
  45   NDC80                 NDC80 homolog                                                       kinetochore complex component                                                                                                                                                                                                                                               n.a                      −0,97
  46   OIP5                  Opa interacting protein 5                                           Required for recruitment of CENPA to centromeres and normal chromosome segregation during mitosis                                                                                                                                                                           −0,61                    −0,74
  47   PARP2                 poly (ADP-ribose) polymerase 2                                      Involved in the base excision repair (BER) pathway,                                                                                                                                                                                                                         −0,33                    −0,49
  48   PBK/TOPK              PDZ-binding kinase                                                  Phosphorylates MAP kinase p38, active only in mitosis. May also play a role in the activation of lymphoid cells. When phosphorylated, forms a complex with TP53, leading to TP53 destabilization and attenuation of G2/M checkpoint during doxorubicin-induced DNA damage   −0,66                    −0,51
  49   PLK1                  Polo-like kinase 1                                                  critical regulatorsof cell cycle progression, mitosis, cytokinesis, and the DNA damage response                                                                                                                                                                             −0,78                    −0,29
  50   PLK4/STK18            Polo-like kinase 4                                                  able to induce centrosome amplification through the simultaneous generation of multiple procentrioles adjoining each parental centriole during S phase. Phosphorylates CDC25C and CHEK2                                                                                     −0,27                    −0,31
  51   PMS1                  DNA mismatch repair protein                                         involved in the repair of mismatches in DNA                                                                                                                                                                                                                                 −1,24                    n.a.
  52   PRC1                  protein regulator of cytokinesis 1                                  Required for KIF14 localization to the central spindle and midbody.                                                                                                                                                                                                         −0,57                    −0,63
  53   PRDM10                PR-domain family member 7                                           transcriptional regulation, involved in B cell differentiation and tumour suppression                                                                                                                                                                                       −1,32                    n.a.
  54   PUM2                  pumilio homolog 2                                                   Sequence-specific RNA-binding protein, support proliferation andself-renewal of stem cells                                                                                                                                                                                  −0,32                    n.a.
  55   RAD1                  Rad1-like DNA damage checkpoint protein                             cell cycle checkpoint protein                                                                                                                                                                                                                                               −0,28                    n.a.
  56   FANCO/RAD51C          RAD51 homolog C                                                     early function in DNA repair in facilitating phosphorylation of the checkpoint kinase CHEK2 and thereby transduction of the damage signal, leading to cell cycle arrest and HR activation                                                                                   −0,32                    n.a.
  57   RAD54B                DNA repair and recombination protein RAD54B                         Involved in DNA repair and mitotic recombination                                                                                                                                                                                                                            −0,96                    −0,45
  58   RAD54L                DNA repair and recombination protein RAD54-like                     Involved in DNA repair and mitotic recombination                                                                                                                                                                                                                            −0,49                    −0,23
  59   RFC3                  replication factor C (activator 1) 3                                elongation of primed DNA templates by DNA polymerase delta and epsilon requires the action of the accessory proteins proliferating cell nuclear antigen (PCNA) and activator 1                                                                                              −0,53                    n.a.
  60   RMI1                  RecQ mediated genome instability 1                                  important role in the processing ofhomologous recombination intermediates to limit DNA crossover formation in cells                                                                                                                                                         −0,54                    n.a.
  61   RNASEN                drosha, ribonuclease type III                                       is involved in the initial step ofmicroRNA (miRNA) biogenesis                                                                                                                                                                                                               −0,71                    n.a.
  62   SAC3D1                SAC3 domain containing 1                                            Involved in centrosome duplication and mitotic progression                                                                                                                                                                                                                  −1,05                    −1,01
  63   SKP2                  S-phase kinase-associated protein 2 - E3 ubiquitin protein ligase   subunit of the SCF ubiquitin ligase                                                                                                                                                                                                                                         −0,95                    
  64   SPAST                 spastin                                                             completion of the abscission stage of cytokinesis                                                                                                                                                                                                                           −0,83                    −0,53
  65   STIL                  SCL/TAL1 interrupting locus                                         its long-term silencing affects cell survival and cell cycle distribution as well as decreases CDK1 activity correlated with reduced phosphorylation of CDK1                                                                                                                n.a                      −0,43
  66   STRADA                STE20-related kinase adaptor alpha                                  necessary for STK11-induced G1 cell cycle arrest                                                                                                                                                                                                                            −0,48                    −0,35
  67   STRA13/FANCM/CENP-X   Fanconi anemia-associated polypeptide                               involved in DNA damage repair and genome maintenance                                                                                                                                                                                                                        −0,38                    −0,275
  68   TACC3                 transforming, acidic coiled-coil containing protein 3               microtubule-associated adaptor protein                                                                                                                                                                                                                                      −0,41                    −0,51
  69   TTK/MPS1              Phosphotyrosine picked threonine-protein kinase                     Essential for chromosome alignment by enhancing AURKB activity (via direct CDCA8 phosphorylation) at the centromere, and for the mitotic checkpoint                                                                                                                         −0,37                    −0,45
  70   TUBG1                 Tubulin G1                                                          major constituent of microtubules,                                                                                                                                                                                                                                          −0,61                    n.a.
  71   UBE2G1                ubiquitin-conjugating enzyme E2G 1                                  member of theE2 ubiquitin-conjugating enzyme family and catalyzes the covalent attachment of ubiquitin to other proteins                                                                                                                                                    −0,77                    −0,55
  72   ZW10                  kinetochore associated, homolog                                     Essential component of the mitotic spindle assembly checkpoint                                                                                                                                                                                                              −0,305                   n.a.

Data are extracted from U133 plus 2.0 microarray analysis. Differentially expressed genes were identified using linear models as implemented in the Bioconductor package LIMMA \[[@R32], [@R68]\]. Shown are the data for αIgM treated BL2 cells (triplicate) and from nine individual CD10^+^ tonsillar B cells stimulated *in vitro*. n.a. -- not affected. BL2 data are part of the heatmap in Figure [1A](#F1){ref-type="fig"} and TABLE [II](#T2){ref-type="table"}, whereas gene expression changes of CD10^+^ tonsillar B cells are extracted from [supplementary Table S3](#SD4){ref-type="supplementary-material"}.

Of the 288 genes comprising the BCR.1 index *PLK1*, *AURKA*, *NEK2*, *BUB1B*, *CDC20, MPS1, BIRC5, HMMR*, *TACC3* and *KIF14A* were selected for validation and verification experiments by qRT-PCR in two independent cell lines \[[@R33]--[@R40]\]. These genes were selected because they are mitotic entry and progression regulating genes. BL2 and Ramos cells were stimulated with αIgM for 3hrs and gene expression changes analysed by qRT-PCR (Figure [2A](#F2){ref-type="fig"}). In line with our microarray data, qRT-PCR analyses show suppression of all selected BCR.1 genes by BCR activation. Furthermore, the expression of these genes was analysed over time following αIgM treatment (Figure [2B](#F2){ref-type="fig"}). Data were taken from a global gene expression analysis in BL2 cells. Cells were stimulated by αIgM and harvested at different time points starting from 30 min after adding αIgM until 480 min. RNA of three independent biological experiments was hybridized to Human ST1.0 microarrays. Most of the genes show a comparable time dependent suppression after αIgM treatment within the first 3-5hrs. Interestingly, some of the genes started to return to their basal expression level within 8hrs, suggesting a temporary effect on cell cycle regulation or corresponding negative feedback mechanism when cells are treated with αIgM (Figure [2B](#F2){ref-type="fig"}).

![Expression of genes from the BCR.1 gene module is deliberately suppressed in lymphoma cells\
**A.** Expression of the genes for *PLK1, AURKA, NEK2, BUB1B, CDC20, MPS1, BIRC5, HMMR, TACC3* and *KIF14A* in response to αIgM treatment was analysed in BL2 and Ramos cells using qRT-PCR. One representative experiment out of three is shown. All samples were analysed in triplicate. Expression of the genes is shown as 2^−ΔΔCT^ relative to *abl* housekeeper expression and compared to unstimulated control. **B.** Time dependent suppression of genes as in Figure [2A](#F2){ref-type="fig"} by αIgM treatment of BL2 cells. Data are taken from Human ST1.0 microarray analysis. Differentially expressed genes were identified using linear models as implemented in the Bioconductor package LIMMA \[[@R68]\].](oncotarget-07-47061-g002){#F2}

Next, we investigated whether BCR activation affects the same genes in lymphoma precursor cells in the same way as in cultured lymphoma cells. Therefore, the expression of cell cycle regulatory genes affected by αIgM treatment in BL2 cells was analysed in human tonsillar CD10^+^ B cells. Data were taken from a global gene expression analysis of CD10^+^ B cells from nine different donors (Table [III](#T3){ref-type="table"}, [Supplementary Table S3](#SD4){ref-type="supplementary-material"}). Although there are single BCR.1 genes that were not suppressed by BCR activation in human tonsillar CD10^+^ B cells, most of the analysed genes are suppressed by BCR stimulation as observed for BL2 cells. Thus, based on the common suppression of BCR.1 genes in cultured B lymphoma cells and in CD10^+^ human B cells, we conclude that this transcriptional regulation represents a common functional pathway of activated BCR signaling.

In addition, cell lines derived from DLBCL, U2932, HT, SUDHL5 and SUDHL6, were analysed for the presence of the BCR.1 index and whether it is affected by αIgM treatment. The BCR.1 index was detectable in HT and U2932 cells ([Supplementary Figure S1A](#SD1){ref-type="supplementary-material"}). Stimulation of DLBCL cell lines with αIgM led to a strong downregulation of BCR.1 genes (index increase) with the exception of SUDHL6 ([Supplementary Figure S1B](#SD1){ref-type="supplementary-material"}), indicating that down-regulation of BCR.1 index genes is also observed in DLBCL.

A prolongation of G2/M transition in αIgM stimulated human B cells {#s2_3}
------------------------------------------------------------------

Since many genes of the BCR.1 gene cluster are involved in the regulation of mitotic processes, we next studied if BCR signaling had an inhibitory effect on mitosis. Cell cycle progression was monitored using flow cytometry to define the percentage of the diploid and tetraploid sets of chromosomes \[[@R41], [@R42]\]. In asynchronously growing BL2 and Ramos cells, αIgM treatment led to a delay in G2/M as revealed by an increase in the percentage of cells with a 4N DNA content (Figure [3A](#F3){ref-type="fig"}). To obtain a better functional insight into the effects of BCR activation on cell cycle regulation, Ramos cells were synchronized at the G1/S transition. After release from thymidine block, cells where left untreated or stimulated by αIgM. Cell cycle progression was monitored using flow cytometry at defined time points as shown in Figure [3B](#F3){ref-type="fig"}. Within 4hrs both untreated or αIgM treated cells entered the G2 phase of the cell cycle. While untreated cells progressed through mitosis within 5-6hrs, αIgM treated cells were delayed by approximately 1-2hrs. Figure [3C](#F3){ref-type="fig"} shows the percentage of the 2N and 4N DNA content. Analyses of the phosphorylation of Histone 3 as a mitotic marker (pHistoneH3) showed that pHistone-H3 peaks after 5hrs in control cells in contrast to αIgM treated cells, which peaks at 6.5hrs (Figure [3D](#F3){ref-type="fig"}). After 8hrs no phosphorylation remains. Interestingly, the phosphorylation of this mitotic marker is generally decreased in cells activated via the BCR. To quantify the effect, the mitotic index of thymidine synchronized BL cells was analysed by measuring the percentage of pMPM3 positive cells. In αIgM treated cells the number of pMPM3 positive cells was lower compared to untreated cells (Figure [3E](#F3){ref-type="fig"}) further supporting the view that the activation of the BCR signaling pathway leads to a delay in G2 and/or lag in progression through the mitotic phase of the cell cycle. This is in agreement with the observed reduced expression of cell cycle regulators from the BCR.1 gene cluster. Immunoblot analysis for Aurora-A, Aurora-B, Tpx2 or Mad2 and the phosphorylated forms of Aurora-A and -B revealed corresponding changes in protein levels and phosphorylation patterns (Figure [3F](#F3){ref-type="fig"}). In line with a delay in mitotic progression, activation (phosphorylation) of the key mitotic kinases, Aurora-A and Aurora-B, was prolonged in BCR-activated BL cells (Figure [3F](#F3){ref-type="fig"}). Untreated cells enter M phase 4-6 hrs after release of the cell cycle block. After 8 hrs most of the cells have left mitosis as shown by a peak of TPX2 levels at 6hrs and the sharp decline of TPX2 after 8hrs (Figure [3F](#F3){ref-type="fig"}). However, cells that have been activated via BCR enter mitosis at the latest after 8hrs and need 10hrs to complete mitosis. The prolongation of the G2 phase as well as the observed delay of entry into mitosis could be an indication that BCR activation suppresses mitotic processes.

![BCR activation is associated with a prolongation of the G2 phase, a deceleration of M phase entrance and metaphase defects\
**A.** Percent of BL2 and Ramos cells in different cell cycle phases with and without αIgM stimulation. Asynchronous growing BL cell line Ramos cells were stimulated by αIgM and cell cycle changes were detected using flow cytometry according to Nicoletti 6h after stimulation. **B.** Monitoring of the passage of synchronized Ramos cells through the cell cycle. Double thymidine block synchronized cells were released from cell cycle block and simultaneously stimulated using αIgM or left untreated. **C.** Percentage of cells within the different cell cycle phases as monitored by flow cytometry as in B. **D.** Changes in Histone 3 phosphorylation of synchronized Ramos cells after release from cell cycle block and simultaneously stimulated using αIgM or left untreated as monitored by immunoblot. **E.** Determination of the percentage of mitotic cells measured by phosphorylation of MPM2 (pMPM2) by flow cytometrical analyses of fixed cells 12h after stimulation. **F.** Thymidine synchronized Ramos cells were released from cell cycle block and treated as in B. Phosphorylation of AUROKA and AUROKB and their expression was monitored in unstimulated and αIgM stimulated cells in comparison to MAD2 and TPX2 as described recently \[[@R42]\]. Changes in Aurora kinase phosphorylation and TPX protein levels as measured by ImageJ quantification analysis shown within the [Supplementary Figure S2](#SD1){ref-type="supplementary-material"}. **G.** Detection of defective metaphases in αIgM stimulated cells quantified by microscopy. Thymidine synchronized Ramos cells were released from cell cycle block and treated as described in B. Two hours before harvesting cells were treated with 10μM MG132. Cells were stained with DAPI. **H.** The percentage of defect metaphases was calculated as monitored by microscopy exemplified in G.](oncotarget-07-47061-g003){#F3}

Therefore, defects in mitosis were investigated and quantified. Synchronized BL cells were released from cell cycle block as described above in the presence or absence of αIgM. 2hrs before harvesting, cells were treated with the proteasome inhibitor MG132 to arrest cells in metaphase. In Ramos cells treated with MG132 alone, metaphase chromosomes were found to be properly aligned at the equatorial plane. Abnormal metaphases were increased in αIgM treated cells (Figure [3H](#F3){ref-type="fig"}), suggesting that BCR signaling causes chromosome missegregation and subsequent accumulation of karyotype abberations.

To test this, a chronic activation of BCR was mimicked by culturing Ramos cells over 3 weeks with daily addition of αIgM F(ab)~2~ fragments. In Figure [4](#F4){ref-type="fig"} A/B cell viability and cell doubling data are presented from these experiments. A decrease of cell viability within the first 10 days was accompanied by a very low cell doubling. This fits well with earlier observations of increased cell death in BL cells after *in vitro* BCR activation monitored as cell cycle arrest within G1 \[[@R43]\]. However, after two weeks both cell proliferation and viability were increased. Analysis of the karyotypes of chronically treated Ramos cells revealed additional chromosomal aberrations including translocations (t(15;21)(q14?;q22)) as well as additions (add(16)(q24)) (Figure [4](#F4){ref-type="fig"}). These structural abnormalities were not observed in untreated BL cells. One explanation for the induction of additional chromosomal abberations could be that chronic exposure of B cells to antigens and thus BCR activation can lead to subsequent cell cycle changes predisposing cells for the acquisition of subsequent chromosomal aberrations.

![Continiously αIgM treated B cells are characterized by additional chromosomal aberrations\
**A.** Ramos cells were treated with αIgM or left untreated for at least 21 days adding αIgM every 24hrs after adjusting cell numbers according to untreated cells. Data are presented as proliferation rate (see additional details within the supplementary Material and Methods section). **B.** Cell viability of Ramos cells was measured by the number of propidium-iodide positive Ramos cells using FACS. **C.** Karyotype of Ramos cells in the absence of BCR activation. Karyotype of Ramos after chronic αIgM stimulation for 21 **D.** and 28 days **E.** respectively. **F.** M-FISH of Ramos cells in the absence of BCR activation. M-FISH of Ramos cells after chronic αIgM stimulation for 21 **G.** and 28 days **H.** respectively. Shown are additional chromosome aberrations of add(16)(q24) after 21d (**D/G**) and of t(15;21)(q14?;q22) after 28days (**E/H**) αIgM treatment respectively.](oncotarget-07-47061-g004){#F4}

Gene suppression is negatively associated with c-Myc activity after B cell receptor activation {#s2_4}
----------------------------------------------------------------------------------------------

It was shown recently that in BL cell lines αIgM treatment is associated with a PI3K dependent decrease in *MYC* expression \[[@R32]\]. Therefore, the involvement of c-Myc in BCR.1 gene regulation, particularly on cell cycle regulators and on cell cycle deregulation induced by αIgM was evaluated.

First, a patient-based comparison between the BCR.1 index with our recently established Myc-index was performed \[[@R20]\]. The correlation coefficients of these two indices were calculated in gene expression profiles of 219 B-NHL including molecularly defined BLs (mBLs), non-mBLs and intermediate lymphoma (molecularly unclassified B-NHLs) \[[@R30]\]. The correlation coefficient is −0.76 (Figure [5A](#F5){ref-type="fig"}). Thus, the BCR.1 index inversely correlates with the c-Myc index. Figure [5A](#F5){ref-type="fig"} shows both index values per sample. Therefore, mBL cases are characterized by a high c-Myc but a low BCR.1 index, whereas non-mBLs and intermediate lymphoma are more heterogeneous with a lower c-Myc and higher BCR.1 index. Lymphomas with a high BCR.1 signal can be characterized by a very low c-Myc activity and therefore can be grouped as BCR.1^high^/Myc^low^ NHL. The majority of non-mBLs and intermediate lymphoma are characterized by corresponding higher BCR.1 but lower c-Myc activity relative to mBLs. Comparison of the BCR.1 index with BCL6 regulated genes was performed in patient samples ([Supplementary Figure S3](#SD1){ref-type="supplementary-material"}) \[[@R28], [@R44]\]. Although a good separation of mBLs from intermediate and non-mBLs was observed, the index correlation (−0.1) was not as strong as for c-Myc. Therefore, the c-Myc protein levels were scored on tissue microarrays (TMA) of 99 lymphoma cases taken from the MMML-cohort described above \[[@R30]\]. In parallel, the BCR.1 index for these cases based on their gene expression profiles was calculated. This analysis revealed that cases with higher numbers of c-Myc positive lymphoma cells were significantly more likely to express BCR.1 genes (low BCR.1 index) (p=0.0012) (Figure [5B](#F5){ref-type="fig"}). This finding underscores the negative correlation of c-Myc and BCR.1 indices and supports the definition of a BCR.1^high^ Myc^low^ NHL subgroup (mainly DLBCL).

![c-Myc is involved in the regulation of cell cycle regulators from the BCR.1 gene cluster\
**A.** The BCR.1 index is inversely correlated with the c-Myc index in distinct groups of lymphoma patients and discriminates Burkitt lymphoma from diffuse large B cell lymphoma. The parallel activity was estimated plotting the BCR.1 and c-Myc indices against each other and calculating the respective correlation coefficient. The correlation coefficients of the BCR.1 index and the c-Myc index were calculated in gene expression profiles of 219 aggressive NHL \[[@R30]\]. The NHL cases were assigned to the following molecular categories: mBL (red), non-mBL (green) and intermediate lymphoma (yellow) based on their gene expression profiles \[[@R30]\]. **B.** The BCR.1 index is inversely correlated to the number of c-Myc positive cells in NHL. c-Myc protein levels were determined using immunohistochemical staining of tissue-microarrays. The scoring was performed as follows: low expression (0-25% positive cells) and high expression (25-100 % positive cells). **C.** B cell receptor activation and c-Myc-inhibition delays the G2/M cell cycle phase transition in an additive way as monitored by the passage of synchronized Ramos cells through the cell cycle. Double thymidine block synchronized Ramos cells were analysed as described in Figure [3](#F3){ref-type="fig"}. **D.** Percentage of cells within the different cell cycle phases monitored by flow cytometry as in C. **E.** qRT-PCR analysis of *BUB1B* gene expression in BL2 (black bars) or Ramos cells (grey bars). BL2 and Ramos cells were pretreated for 3h with 60μM 10058-F4 c-Myc inhibitor or solvent (DMSO). Cells were stimulated for an additional 3h with αIgM F(ab)2 fragment (12μg/ml). qRT-PCR analyses were performed using SYBR green. Fold changes were calculated using the ΔΔCt method. One representative experiment of three replicates is shown. Additional BCR.1 genes are shown in the extended view figure E1. **F.** c-Myc binds to the *BUB1B* gene. A fragment was amplified that encompasses the previously described E-box in intron 1 of the *BUB1B* gene \[[@R45]\]. ChIP was performed using antibodies directed against IgG as a negative control (lanes 3,4), against c-Myc (lanes 5,6) and against acetylated histone H3 as positive control (marker for active transcription) (lanes 7,8). c-Myc binds to the *BUB1B* gene (lane 5) but this binding is lost as a result of B cell receptor activation (lane 6). The lower electropherogram shows a shorter exposure time to show differences in acetyl Histone H3 binding.](oncotarget-07-47061-g005){#F5}

To assess whether the cell cycle delay after BCR activation might be the result of the BCR induced inhibition of c-Myc, we investigated whether the inhibition of c-Myc alone can induce G2-phase prolongation of thymidine synchronized Ramos cells. Double thymidine block synchronized Ramos cells were released from cell cycle block and treated with the chemical Myc inhibitor 10058-F4, αIgM, or both. Within 4hrs all cells entered the G2 phase of the cell cycle. While untreated cells entered the G1 phase of the cell cycle within 5-6hrs αIgM, 10058-F4 and αIgM/10058-F4 treated cells were delayed (Figure [5C](#F5){ref-type="fig"}). The prolonged G2 phase in 10058-F4 treated cells was comparable to the effect of αIgM treatment alone and thus supports the inverse correlation of BCR.1 and the Myc index shown in Figure [5A/B](#F5){ref-type="fig"}. The strongest delay was observed by the combination of BCR activation and c-Myc inhibition. Therefore, αIgM treatment together with 10058-F4 shows an additive effect on G2 phase prolongation. This suggests that the BCR effect on the cell cycle regulation is not solely the result of inhibiting *MYC* expression. In Figure [5D](#F5){ref-type="fig"} the percentage of the diploid and tetraploid sets of chromosomes is shown.

The role of aberrant c-Myc activity on cell cycle and BCR.1 gene regulation was analysed by qRT-PCR as shown for *BUB1B* and other BCR.1 genes in BL2 and Ramos cells treated with 10058-F4, αIgM or both (Figure [5E](#F5){ref-type="fig"}, [Supplementary Figure S4](#SD1){ref-type="supplementary-material"}). The expression of some BCR.1 genes is dependent on aberrant c-Myc activity, but BCR activation and c-Myc inhibition act in an additive manner.

In addition we tested by chromatin-immunoprecipitation (ChIP) whether c-Myc binding to a known E-box containing region in the first intron of the *BUB1B* gene is altered upon BCR activation \[[@R45], [@R46]\]. The gene locus of the *BUB1B* gene was enriched by ChIP of c-Myc in unstimulated cells (Figure [5F](#F5){ref-type="fig"}). Importantly, following BCR activation this enrichment was abolished. As positive control a ChIP of acetylated histone H3 was used as a marker for active transcription. Therefore, a critical cell cycle regulator is suppressed in response to suppression of *MYC* gene expression by αIgM. However, the observed additive effect of BCR activation together with 10058-F4 treatment also indicates that additional pathways are involved through BCR activation which could mediate the suppression of the BCR.1 genes.

The BCR.1 gene module characterizes individual NHL and is more active within GCB-like DLBCL {#s2_5}
-------------------------------------------------------------------------------------------

To further study the functional relevance of the BCR.1 gene module in specific subgroups of B-NHL and specifically in DLBCL, we compared by the gene expression profiles of 389 primary lymphoma samples \[[@R30], [@R47]\]. Figure [6A](#F6){ref-type="fig"} shows that mBLs (colored in red) are characterized by a low or absent BCR.1 index. This was also observed for samples characterized by *MYC*-aberrations. About 20% of analysed non-mBLs show a strong coherently low expression of BCR.1 genes and therefore are characterized by a strong corresponding BCR signal. This is in good agreement with the observation presented in Figure [1B](#F1){ref-type="fig"} within the "training cohort" and the observed inverse correlation of the BCR.1 and c-Myc indices (Figure [5A](#F5){ref-type="fig"}). A comparison of ABC- and GCB-like DLBCLs in this analysis is difficult as mBLs are labelled also as GCB-like lymphomas. Therefore, an additional analysis was performed (Figure [6B](#F6){ref-type="fig"}). Comparing 281 non-mBL DLBCL samples, we observed a significantly higher BCR.1 index in GCB-DLBCL (n=159) compared with ABC-like DLBCL (n=122) (p=9.35e−06). This supports the view that more GCB-like DLCBL are characterized by a specific coexpression of BCR.1 genes than are ABC-like DLBCL.

![The BCR.1 index characterizes individual aggressive NHL and discriminates between ABC- and GCB-like DLBCL\
**A.** The heatmap is showing the expression of BCR.1 genes (row) in molecular profiles of 389 primary lymphoms samples (columns) from distinct patient cohorts \[[@R30], [@R47]\]. The patient samples are ordered according to rising BCR.1 index from left to right. The colour-coded bar on top of the heatmaps represents the affiliation of patients tomBL (red), non-mBL (green) and yellow (intermediate) diagnosis. **B.** Boxplot of the distribution of indices for BCR-repressed genes comparing 281 DLBCL samples based on their relation to GCB- and ABC-like DLBCL classification. The difference is highly significant with p=9.35e−06.](oncotarget-07-47061-g006){#F6}

DISCUSSION {#s3}
==========

Gene expression based molecular tumour signatures have been identified in aggressive NHL. In DLBCL specific oncogenic signalling networks have been deduced from these signatures. These networks are driven by mutations or the microenvironment acting onto the lymphoma cells \[[@R1], [@R13], [@R48], [@R49]\]. However, the functional effects revealed by these gene expression signatures, are poorly understood. A better understanding could improve of lymphoma treatments. Therefore, the present study aimed to gain further functional insights into oncogenic pathways active in aggressive NHL. The guided clustering approach was extended to identify transcriptional modules that are conserved between patients and *in vitro* stimulated cells but dominantly activated or inhibited by for example BCR signaling but not by other well known mediators of signalling in B cells. We have provided a comprehensive genome-wide resource for the functional exploration of molecular and cellular regulation in B cells. Ten new transcriptional modules were identified (Figure [1](#F1){ref-type="fig"}).

Of the ten transcriptional modules we identified, the BCR.1 module comprises genes, which are suppressed by BCR activation. It was shown that these genes are downregulated by BCR activation in a number of different cell lines including BL2, Ramos, U2932, HT and SUDHL5. We conclude that in patients BCR or related pathways are involved in the described way of gene coregulation. Furthermore, the BCR.1 module is strong in a substantial number of GCB-like DLBCL but not in mBL and supports the hypothesis, that in some DLBCL BCR signaling is involved in the downregulation of cell cycle regulators. Because in ABC-like DLBCLs the BCR.1 signal is attenuated compared to GCB-like DLBCLs (Figure [6B](#F6){ref-type="fig"}), it would be interesting to determine if the coactivity of classical Jak/STAT and NF-κB signaling characteristic of ABC-like DLBCL can enhance the BCR.1 gene expression independent of c-Myc \[[@R19], [@R50]\].

Remarkably, BCR.1 genes are enriched for those involved in cell cycle regulation (Figure [2](#F2){ref-type="fig"} and Table [III](#T3){ref-type="table"}). The functional outcome of this gene module is a delayed entry to and progression of mitosis most probably as a result of reduced expression of the identified cell cycle regulators (Figure [3](#F3){ref-type="fig"}). After continuous BCR activation some B cells gain additional genetic aberrations (Figure [4](#F4){ref-type="fig"}) as a direct or indirect consequence of the observed changes in G2/M cell cycle phase delays. By large-scale follow-up analyses of pairs of primary and relapsed aggressive NHL it can now be tested which role BCR.1 gene expression is playing to affect increases of chromosomal aberrations or disease progression. However, this is also an important observation as the genes suppressed by BCR activation are also found to be downregulated in isolated human tonsillar CD10^+^ B cells. Therefore, it is proposed that these genes are functionally relevant in both transformed and in reactive B cells.

There is growing evidence of a role for BCR signaling in the pathogenesis of different subtypes of NHL. In BL a tonic BCR signal is observed whereas in DLBCL both tonic and chronic active BCR signaling seem to be important \[[@R26], [@R27], [@R51]--[@R53]\]. As well as supporting B cell proliferation, survival or differentiation, BCR activation can also induce G1 cell cycle arrest, apoptosis and increased cell death in different B cells \[[@R54]--[@R59]\]. Our observations suggest that these suicide pathways can be, at least partially, attributed to a delay in G2/M with associated mitotic defects potentially leading to subsequent chromosomal aberrations. Our data also provide a plausible mechanism to explain the link between inflammation and the development of lymphomagenic mutations; especially in DLBCL with a high BCR.1, chronic inflammation and/or chronic antigen driven activation of oncogenic pathways with no or low c-Myc activity. The inverse correlation of the Myc-index and the BCR.1 index suggests that in lymphomas with a high *MYC* expression corresponding BCR.1 genes are highly expressed (low BCR.1 index, high gene expression) and thus most likely indicates an absence of a strong antigen stimulation.

The newly identified oncogenic network present in a substantial number of GCB-like DLBCL will likely define more rational treatment targets in this heterogeneous disease. Whether this has implications for stratifying NHL patients for molecular-based prognostication and for targeted therapy has to be investigated in new clinical trials using R-CHOP and/or currently introduced targeted drugs for Btk, PI3K and NF-kB pathways or BET-domain containing protein inhibitors \[[@R25], [@R48], [@R51], [@R60]\].

MATERIALS AND METHODS {#s4}
=====================

Cell culture {#s4_1}
------------

BL2, Ramos, SUDHL5, SUDHL6, U2932 and HT (all obtained from the DSMZ Braunschweig, Germany) cell cultivation as well as purification and sorting of primary human tonsillar B cells was performed as previously described \[[@R20], [@R61]\] \[[@R32]\]. A detailed protocol can be found in the "Extended View Methods Section". For stimulation studies, cells were cultured as described previously \[[@R32]\]. Cells chronically activated by αIgM were grown for up to 28 days and αIgM was added every 24hrs. Cells were harvested using corresponding inhibitors of phosphatases and proteases and RNA isolated using the RNeasy Plus Mini Kit (Qiagen). Cell doubling and viability was determined by counting cells in the presence of trypan blue.

Synchronisation of BL cells was performed using thymidine treatment as recently described \[[@R62]\]. Cell cycle analysis was performed on the basis of analysing the DNA content in the nuclei of the cells by propidium iodide staining followed by flow cytometry. For a detailed description see the "Expanded View Methods Section".

Gene expression analysis {#s4_2}
------------------------

qRT-PCR was performed using SYBR green. ΔCt values were normalised to ß2m and abl expression and ΔΔCt values calculated. Oligonucleotides used are summarized in [Supplementary Table S4](#SD5){ref-type="supplementary-material"}. For whole genome microarrays Human Genome U133A 2.0 plus Arrays (Affymetrix) or Human ST1.0 Arrays (Affymetrix) as indicated was performed according to manufacturer\'s recommendations by the TAL (UMG, Germany) For further details of gene expression analyses see the "Expanded View Methods Section".

Cytogenetic analysis {#s4_3}
--------------------

Metaphases were analysed using chromosome banding analysis and 24-color FISH. Chromosome preparation was performed using standard cytogenetic protocols and modified chromosome banding technology (GAG// Giemsa bands of acetic Saline Giemsa). M-FISH (24 color FISH) was done according to the manufacturer\'s protocol (MetaSystems). Karyotypes were classified according to the International System for Human Cytogenetic Nomenclature (ISCN) \[[@R63]\].

Chromatin immunoprecipitation {#s4_4}
-----------------------------

BL2 cells were stimulated with 1.3μg/ml αIgM F(ab)~2~ fragments for 3hrs or left untreated as control. Cells were sedimented and resuspended in PBS containing 1.42% formaldehyde and incubated for 15min at room temperature. Chromatin-Immunoprecipitation was conducted as described previously using 2μg anti c-Myc (clone N-262, Santacruz), 2μg anti acH3 (clone 06-599, Millipore), 2μg αIgG control (ab46540, abcam) antibodies. A detailed protocol is presented in the "supplemental Material and Methods section".

Case selection and classification for immunohistochemistry {#s4_5}
----------------------------------------------------------

127 B-cell lymphoma samples were obtained from the files of the lymph node registry Kiel with ethical approval and classified according to the WHO classification using standard histological, immunohistochemical and molecular criteria \[[@R64]\]. In addition, 20 specimens obtained within the framework of the network project "Molecular Mechanisms in malignant Lymphoma" (MMML) were analysed. The latter cohort was diagnosed and classified based on the previously reported molecular signatures \[[@R30]\]. All lymphomas were analysed using tissue-micro-arrays (TMA) containing 2 cores of 1 mm or 0.6 mm (for the MMML specimen) for each case (ethical approval Ref. Nr. 1/1/05).

Bioinformatic analyses and analysed datasets {#s4_6}
--------------------------------------------

The identification of pathway activation clusters was performed using the Guided Clustering algorithm \[[@R28]\]. Guided Clustering identifies genes specific for one of the five stromal stimuli (BCR, CD40L, BAFF, IL-21, LPS). Within this framework the stimulated BL2 cells act as guiding data whereas the cohort of Myc-negative DLBCL represent the guided dataset \[[@R30]\]. The definition of the required binary vector depends on the respective stimulation with the numerical value 1 for the stimulus and 0 for the remaining stimuli as well as for the controls. For each stimulation two clusters were extracted, showing an opposite regulation. The respective genes in each cluster may represent a potential surrogate marker for pathway activity in lymphoma samples. To determine the extent of gene cluster activity in lymphoma patients, one index was calculated by gene cluster and per lymphoma sample. Expression values from those genes assembling the individual cluster were used to calculate a single representative value (the index) for each sample by fitting a standard additive model with independent gene and sample effects using Tukey\'s median polish procedure as described \[[@R65]\]. The index values of genes inhibited by a stimulus (.1 modules (eg BCR.1)) were multiplied by minus one to enable the interpretation of the indices as absence or presence of stimulation. Hence, down-regulation of these genes leads to a high index value (stimulation is present) whereas a low index value indicates the absence of any regulatory effect due to stimulation. Gene set enrichment analysis (GSEA) of ranked gene list was performed using the Java implementation of GSEA obtained from <http://www.broadinstitute.org/gsea/>. GSEA was conducted in the mode for pre-ranked gene lists on the C2 set of curated gene signatures from the Molecular Signature Database (MSigDB). Genes are attributed to one ore more biological processes, molecular function and cellular location with respect to the Gene Ontology as well as pathways in the KEGG database \[[@R66], [@R67]\]. Hypergeometric testing was performed to test for non-random overrepresentation of module genes in each of these terms based on the hypergeometric distribution model. This GO/KEGG analyses was implemented in customized inhouse scripts.

The primary data are available from GEO (<http://www.ncbi.nlm.nih.gov/geo/>) - raw data for gene expression changes for LPS, CD40L, BAFF, IL-21 and αIgM stimulated BL2 cells are available under accession no. GSE42660 and GSE29700 \[[@R28], [@R32]\], data for CD10^+^ human tonsillar B cells (GSE71724), pathway inhibition (GSE68761) and gene expression kinetics (GSE71721) are summarized as SuperSeries record GSE71725.
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